![]() During this conference call, in order to provide greater transparency regarding our operating performance, we refer to certain non-GAAP financial measures that involve adjustments to GAAP results. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements. Additional information regarding these factors appears under the heading Cautionary Note regarding forward-looking statements in the slide deck we issued this afternoon, and under the heading Risk Factors in our most recent Form 10-K and our second quarter Form 10-Q filed with the Securities and Exchange Commission and available at sec.gov and on our website at as well as subsequent filings with the SEC. A press release announcing our results is currently available on our website at, and an audio archive of this conference call will be available on our website later today.īefore we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including information relating to the future of Novavax, its key strategic priorities, plans and prospects for 2022 and financial guidance including revenue and gross margin the ongoing development of our vaccine candidates, including anticipated timing of trials and results the scope, timing and outcome of future regulatory filings and actions the efficacy, safety and intended utilization of our vaccine candidates the global market opportunities for our vaccine candidates the future availability of our vaccine candidates and key upcoming milestones.Įach forward-looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. Good afternoon, and thank you all for joining us today to discuss our second quarter 2022 operational highlights and financial results. I would now like to turn the conference over to Silvia Taylor, Senior Vice President of Global Corporate Affairs and Investor Relations. Please note, this event is being recorded. After today’s presentation, there will an opportunity to ask questions. All participants will be in listen-only mode. Good morning and welcome to Novavax Second Quarter 2022 Financial Results and Operational Highlights Conference Call. Greg Glenn - President-Research and Development Jim Kelly - Chief Financial Officer and Treasurer John Trizzino - Chief Commercial Officer and Chief Business Officer Stan Erck - President and Chief Executive Officer Silvia Taylor - SVP, Global Corporate Affairs and Investor Relations ![]() ( NASDAQ: NVAX) Q2 2022 Earnings Conference Call Aug4:30 PM ET
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |